keyword
MENU ▼
Read by QxMD icon Read
search

Azilsartan randomized

keyword
https://www.readbyqxmd.com/read/30302936/efficacy-and-safety-of-azilsartan-medoxomil-chlortalidone-fixed-dose-combination-in-hypertensive-patients-uncontrolled-on-azilsartan-medoxomil-alone-a-randomized-trial
#1
David J Collier, Attila Juhasz, Enrico Agabiti-Rosei, Eric Lloyd, Michie Hisada, Lin Zhao, Stuart Kupfer, Mark J Caulfield
Patients with grade 2-3 essential hypertension and postplacebo mean clinic systolic blood pressure (SBP) 160-190 mm Hg and 24-hour SBP 140-175 mm Hg by ambulatory blood pressure monitoring (ABPM) received 40 mg azilsartan medoxomil (AZL-M) monotherapy for 4 weeks. "Nonresponders" were then randomized to 8 weeks of double-blind treatment with AZL-M 40 mg, AZL-M/chlortalidone (CLD) 40/25, or AZL-M/CLD 40/12.5 mg. After 8 weeks, mean clinic SBP change was -21.1 (±1.04) mm Hg for AZL-M/CLD 40/25 mg, -15...
October 2018: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/30217371/comparison-of-effectiveness-of-azilsartan-medoxomil-and-olmesartan-in-blacks-versus-whites-with-systemic-hypertension
#2
Keith C Ferdinand, George L Bakris, William C Cushman, Michael A Weber, Eric Lloyd, Jingtao Wu, William B White
Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II receptor blocker azilsartan medoxomil (AZL-M) and the fixed-dose combination of AZL-M with chlorthalidone (AZL-M/CLD) versus the ARB olmesartan (OLM) and the OLM fixed-dose combination with hydrochlorothiazide (OLM/HCTZ). One analysis pooled 1,610 patients from two 6-week randomized controlled trials to compare once daily AZL-M 40mg, AZL-M 80mg, OLM 40mg, and placebo. The second analysis included 1,020 patients from a 12-week randomized controlled trial to compare once daily AZL-M/CLD 40/25mg, AZL-M/CLD 80/25mg, and OLM/HCTZ 40/25mg...
August 4, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/30175930/a-randomized-trial-of-the-efficacy-and-safety-of-azilsartan-medoxomil-combined-with-chlorthalidone
#3
Michael A Weber, Peter Sever, Attila Juhasz, Andrew Roberts, Charlie Cao
INTRODUCTION: We measured the effects of azilsartan medoxomil co-administered with chlorthalidone 25 mg in stage 2 hypertension. METHODS: Azilsartan medoxomil 40 or 80 mg plus chlorthalidone were compared with placebo plus chlorthalidone once daily in a randomized, double-blind, 6-week trial. The primary endpoint was change from baseline in 24-hour mean systolic blood pressure by ambulatory blood pressure monitoring. RESULTS: Patients ( N=551; mean age 59 years; 51...
July 2018: Journal of the Renin-angiotensin-aldosterone System: JRAAS
https://www.readbyqxmd.com/read/30122937/azilsartan-improves-the-effects-of-etanercept-in-patients-with-active-rheumatoid-arthritis-a-pilot-study
#4
Naza Mohammed Ali Mahmood, Saad Abdulrahman Hussain, Raouf Rahim Mirza
Background and aim: Much evidence has emerged documenting the involvement of the renin-angiotensin system (RAS) in inflammatory processes. The objective of this study was to evaluate the effects of blocking RAS with azilsartan (Azil) on the clinical efficacy of etanercept (Etan) in patients with active rheumatoid arthritis (RA). Patients and methods: Forty-two patients diagnosed with active RA and poorly responding to methotrexate were enrolled in this pilot clinical study...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29974299/rationale-and-design-of-the-multicenter-trial-on-japan-working-group-on-the-effects-of-angiotensin-receptor-blockers-selection-azilsartan-vs-candesartan-on-diastolic-function-in-the-patients-suffering-from-heart-failure-with-preserved-ejection-fraction-j-taste
#5
Hiroyuki Takahama, Masanori Asakura, Yukio Abe, Masayoshi Ajioka, Kazutaka Aonuma, Toshihisa Anzai, Takaharu Hayashi, Shinya Hiramitsu, Hiroya Kawai, Hidetaka Kioka, Kazuo Kimura, Young-Jae Lim, Ken Matsuoka, Hirohiko Motoki, Yoji Nagata, Sunao Nakamura, Nobuyuki Ohte, Yukio Ozaki, Taishi Sasaoka, Shunsuke Tamaki, Toshimitsu Hamasaki, Masafumi Kitakaze
BACKGROUND: Previous studies suggest that the pathophysiology of heart failure with preserved ejection fraction (HFpEF) is characterized not only by high ventricular stiffness, but also by vascular stiffness. Azilsartan has higher vascular affinity compared with other angiotensin II receptor blockers (ARBs), which were proven to have no beneficial effects on clinical outcomes in patients with HFpEF in earlier clinical trials. We aimed to test the hypothesis that azilsartan may improve left ventricular diastolic function in HFpEF patients with hypertension in this trial...
August 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29971568/antihypertensive-effect-of-azilsartan-versus-olmesartan-in-patients-with-essential-hypertension-a-meta-analysis
#6
Di Zhao, Hui Liu, Pingshuan Dong
OBJECTIVE: The comparison of antihypertensive effects between azilsartan and olmesartan in patients with essential hypertension has been investigated in several studies. The results were not consistent. We performed this meta-analysis determining the antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension. METHODS: Pubmed, Web of Science, and Cochrane Central were searched for all published randomized studies comparing the antihypertensive effects between azilsartan and olmesartan in patients with essential hypertension...
July 3, 2018: Irish Journal of Medical Science
https://www.readbyqxmd.com/read/29888275/azilsartan-as-add-on-treatment-with-methotrexate-improves-the-disease-activity-of-rheumatoid-arthritis
#7
RANDOMIZED CONTROLLED TRIAL
Naza Mohammed Ali Mahmood, Saad Abdulrahman Hussain, Hawar Ali Ehsan Kaka Khan
Objective: The present study aimed to evaluate the efficacy and safety of azilsartan (Azil) as "add-on" treatment with methotrexate (MTX) in patients with active rheumatoid arthritis (RA). Methods: This single center, randomized, placebo-controlled, double-blind, pilot study included 64 patients with active RA. Patients received either placebo or Azil in addition to their currently used MTX doses for 90 days. The primary outcomes were DAS-28, SDAI, HAQ-DI, CDAI, EGA, and swollen and tender joints count...
2018: BioMed Research International
https://www.readbyqxmd.com/read/29683146/effects-of-olmesartan-and-azilsartan-on-albuminuria-and-the-intrarenal-renin-angiotensin-system
#8
Takeshi Takami, Sadanori Okada, Yoshihiko Saito, Yoko Nishijima, Hiroyuki Kobori, Akira Nishiyama
Purpose: Olmesartan and azilsartan decrease blood pressure more effectively than other angiotensin receptor blockers (ARBs). ARBs additionally decrease the urinary albumin to creatinine ratio (UACR), a urinary albumin marker, and urinary angiotensinogen (u-AGT), an intrarenal renin-angiotensin system activity marker. We examined the effects of these ARBs on blood pressure, UACR, and u-AGT in patients with uncontrolled hypertension. Methods: Patients with uncontrolled hypertension treated with conventional ARBs, excluding olmesartan and azilsartan, for over 8 weeks were enrolled...
January 2018: World journal of research and review
https://www.readbyqxmd.com/read/29445520/efficacy-and-safety-of-azilsartan-medoxomil-an-angiotensin-receptor-blocker-in-korean-patients-with-essential-hypertension
#9
Attila Juhasz, Jingtao Wu, Michie Hisada, Tomoka Tsukada, Myung Ho Jeong
Background: This was a phase 3, randomized, double-blind, placebo-controlled study. Methods: Adult Korean patients with essential hypertension and a baseline mean sitting clinic systolic blood pressure (scSBP) ≥150 and ≤180 mmHg were randomized to 6-week treatment with placebo ( n  = 65), azilsartan medoxomil (AZL-M) 40 mg ( n  = 132), or AZL-M 80 mg ( n  = 131). The primary endpoint was the change from baseline to week 6 in trough scSBP. Results: The least-squares mean (standard error) change from baseline in trough scSBP in the placebo, AZL-M 40-mg, and 80-mg groups at week 6 were - 8...
2018: Clinical Hypertension
https://www.readbyqxmd.com/read/29334491/a-randomized-titrate-to-target-study-comparing-fixed-dose-combinations-of-azilsartan-medoxomil-and-chlorthalidone-with-olmesartan-and-hydrochlorothiazide-in-stage-2-systolic-hypertension
#10
William C Cushman, George L Bakris, William B White, Michael A Weber, Domenic Sica, Andrew Roberts, Eric Lloyd, Stuart Kupfer
BACKGROUND: Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD). OBJECTIVE/METHODS: We compared FDCs of AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg if needed or AZL-M/CTD 40/12.5 mg once daily titrated to 80/25 mg if needed with an olmesartan medoxomil (OLM)-hydrochlorothiazide (HCTZ) 20/12.5 mg FDC once daily titrated to 40/25 mg if needed in a randomized, double-blind, 8-week study of 1085 participants with clinic SBP 160-190 mmHg and DBP 119 mmHg or less...
April 2018: Journal of Hypertension
https://www.readbyqxmd.com/read/29239867/effects-of-triple-combination-therapy-with-azilsartan-amlodipine-hydrochlorothiazide-on-office-home-blood-pressure-a-randomized-controlled-trial-in-japanese-essential-hypertensive-patients
#11
RANDOMIZED CONTROLLED TRIAL
Hiromi Rakugi, Kohei Shimizu, Yuhei Sano, Yuya Nishiyama, Yoshinobu Kinugawa, Souhei Terashio
OBJECTIVE: The efficacy and safety of triple therapy with azilsartan (AZI), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) compared with dual therapy with AZI/AML or HCTZ monotherapy were evaluated in Japanese essential hypertensive patients in a double-blinded manner. PATIENTS AND METHODS: A total of 353 patients with office blood pressure (BP) of at least 150/95 mmHg were randomized to a 10-week treatment with AZI/AML/HCTZ 20/5/12.5 mg, AZI/AML/HCTZ 20/5/6...
April 2018: Blood Pressure Monitoring
https://www.readbyqxmd.com/read/28681550/comparison-of-long-term-safety-of-fixed-dose-combinations-azilsartan-medoxomil-chlorthalidone-vs-olmesartan-medoxomil-hydrochlorothiazide
#12
RANDOMIZED CONTROLLED TRIAL
Joel M Neutel, William C Cushman, Eric Lloyd, Bruce Barger, Alison Handley
This 52-week, randomized, open-label study evaluated long-term safety/tolerability of fixed-dose combination azilsartan medoxomil/chlorthalidone (AZL-M/CLD) vs fixed-dose combination olmesartan medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients with essential hypertension (stage 2; clinic systolic blood pressure 160-190 mm Hg). Initial AZL-M/CLD 40/12.5 mg/d (n=418) or OLM/HCTZ 20/12.5 mg/d (n=419) could be uptitrated during weeks 4 to 52 (AZL-M/CLD to 80/25 mg; OLM/HCTZ to 40/25 mg [United States] or 20/25 mg [Europe]) to meet blood pressure targets...
September 2017: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/28496022/comparison-of-efficacy-and-safety-of-azilsartan-and-olmesartan-in-patients-with-essential-hypertension
#13
RANDOMIZED CONTROLLED TRIAL
Yuhei Shiga, Shin-Ichiro Miura, Kota Motozato, Kenji Norimatsu, Masaya Yano, Yuka Hitaka, Sen Adachi, Takashi Kuwano, Ken Inoue, Asao Inoue, Kazuaki Fujisawa, Tetsuro Shirotani, Takaaki Kusumoto, Munehito Ideishi, Keijiro Saku
Many patients still have high blood pressure (BP) after treatment with angiotensin II type 1 (AT1 ) receptor blockers (ARBs). We compared the efficacy and safety of azilsartan to those of olmesartan in a prospective randomized clinical trial. Sixty-four hypertensive patients who were treated with ARBs other than azilsartan and olmesartan were enrolled in this study. We randomly assigned patients to changeover from their prior ARBs to either azilsartan or olmesartan, and followed the patients for 3 months. Systolic BP (SBP) in the azilsartan group was significantly decreased at 3 months, and diastolic BP (DBP) and pulse rate (PR) in the olmesartan group showed significant reductions after 3 months...
May 31, 2017: International Heart Journal
https://www.readbyqxmd.com/read/28493376/evaluation-of-the-angiotensin-ii-receptor-blocker-azilsartan-medoxomil-in-african-american-patients-with-hypertension
#14
RANDOMIZED CONTROLLED TRIAL
Wallace Johnson, William B White, Domenic Sica, George L Bakris, Michael A Weber, Alison Handley, Alfonso Perez, Charlie Cao, Stuart Kupfer, Elijah B Saunders
The efficacy and safety of azilsartan medoxomil (AZL-M) were evaluated in African-American patients with hypertension in a 6-week, double-blind, randomized, placebo-controlled trial, for which the primary end point was change from baseline in 24-hour mean systolic blood pressure (BP). There were 413 patients, with a mean age of 52 years, 57% women, and baseline 24-hour BP of 146/91 mm Hg. Treatment differences in 24-hour systolic BP between AZL-M 40 mg and placebo (-5.0 mm Hg; 95% confidence interval, -8...
July 2017: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/28290893/-hronotherapy-aspects-of-efficiency-azilsartan-medoxomil-in-combination-therapy-in-patients-with-hypertension-and-metabolic-syndrome
#15
V V Skibitskiy, A V Fendrikova, D V Sirotenko, A V Skibitskiy
OBJECTIVE: Determination of the effectiveness and safety of different dosing regimens during the day (in the morning or at bedtime) combination therapy including azilsartan medoxomil in patients with essential hypertension and metabolic syndrome (MS). DESIGN AND METHODS: The study included 60 patients with uncontrolled hypertension and MS (age median - 59 (54-65) years). Patients were randomized in two groups: group 1 (n=30) received azilsartan medoxomil 40 mg/day, and indapamide retard 1,5 mg/day in the morning; group 2 (n=30)- azilsartan medoxomoil 40 mg at bedtime and indapamide retard 1,5 mg in the morning...
October 2016: Kardiologiia
https://www.readbyqxmd.com/read/28290827/-azilsartan-medoxomil-capabilities-in-arterial-hypertension-and-obesity
#16
REVIEW
Y A Vasyuk, E Y Shupenina, V V Nesvetov, E A Nesterova, E I Golubkova
Arterial hypertension (AH) is one of the most common cardiovascular disease. Angiotensin II (AT II), the hormone of renin-angiotensin-aldosterone system, realizes its negative effects through AT 1 receptors - application point of angiotensin receptor blockers (ARB). Due to different dissociation AT 1 receptors properties some ARBs are more effective than others. Multiply multicenter randomized and observational studies approve the effectiveness and safety of azilsartan medoxomil in patients with AH 1-2 grade...
December 2016: Kardiologiia
https://www.readbyqxmd.com/read/28079534/practical-efficacy-of-olmesartan-versus-azilsartan-in-patients-with-hypertension-a-multicenter-randomized-controlled-trial-muscat-4-study
#17
RANDOMIZED CONTROLLED TRIAL
Yuki Kakio, Haruhito A Uchida, Ryoko Umebayashi, Hidemi Takeuchi, Yuka Okuyama, Yoshihisa Hanayama, Jun Wada
BACKGROUND: Olmesartan and azilsartan, angiotensin II receptor blockers (ARBs), are expected to decrease blood pressure more than the other ARBs. We conducted randomized-controlled trials to compare the practical efficacy of olmesartan with azilsartan. METHODS: Eighty-four patients treated with the conventional ARBs for more than 3 months were assigned randomly to receive either 20 mg of olmesartan (olmesartan medoxomil, OL group) or 20 mg of azilsartan (azilsartan, not azilsartan medoxomil, AZ group) once daily for 16 weeks...
April 2017: Blood Pressure Monitoring
https://www.readbyqxmd.com/read/27829955/efficacy-and-safety-of-a-single-pill-fixed-dose-combination-of-azilsartan-and-amlodipine
#18
Kota Motozato, Shin-Ichiro Miura, Yuhei Shiga, Takaaki Kusumoto, Keijiro Saku
BACKGROUND: Guidelines for the management of hypertension recommend the use of drugs with different mechanisms of action in antihypertensive regimens that include single-pill fixed-dose combinations of medications. There is some controversy regarding which single-pill fixed-dose combinations of angiotensin II type 1 receptor blockers (ARBs) and calcium channel blockers (CCBs) are effective at reducing blood pressure (BP). METHODS: Forty hypertensive patients who were receiving a single-pill fixed-dose combination of valsartan 80 mg/day and amlodipine 5 mg/day or irbesartan 100 mg/day and amlodipine 5 mg/day were enrolled...
December 2016: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/27824680/angiotensin-ii-receptor-blockers-following-intravenous-nicardipine-administration-to-lower-blood-pressure-in-patients-with-hypertensive-intracerebral-hemorrhage-a-prospective-randomized-study
#19
RANDOMIZED CONTROLLED TRIAL
Joji Inamasu, Shunsuke Nakae, Kazuhide Adachi, Yuichi Hirose
BACKGROUND AND OBJECTIVE: In patients with hypertensive intracerebral hemorrhage (HICH), intravenous nicardipine is primarily used to lower blood pressure (BP). However, there are few studies investigating the role of oral antihypertensives administered after intravenous nicardipine to prevent BP from rising. Angiotensin II receptor blockers (ARBs) may be beneficial in HICH patients not only as antihypertensives but also by lowering plasma catecholamine levels. A prospective randomized study was conducted between January 2015 and March 2016 to comparatively evaluate the efficacy of two ARBs (azilsartan vs...
February 2017: Blood Pressure Monitoring
https://www.readbyqxmd.com/read/27635180/depressor-and-anti-inflammatory-effects-of-angiotensin-ii-receptor-blockers-in-metabolic-and-or-hypertensive-patients-with-coronary-artery-disease-a-randomized-prospective-study-diamond-study
#20
Sen Adachi, Shin-Ichiro Miura, Yuhei Shiga, Tadaaki Arimura, Takashi Kuwano, Ken Kitajima, Amane Ike, Makoto Sugihara, Atsushi Iwata, Hiroaki Nishikawa, Natsumi Morito, Keijiro Saku
BACKGROUND: We compared the efficacy and safety of azilsartan to those of olmesartan in a prospective, randomized clinical trial. METHODS: Forty-four hypertensive patients who had coronary artery disease (CAD) were enrolled. We randomly assigned patients to changeover from their prior angiotensin II receptor blockers (ARBs) to either azilsartan or olmesartan, and followed the patients for 12 weeks. RESULTS: Office systolic blood pressure (SBP) in the azilsartan group was significantly decreased after 12 weeks...
October 2016: Journal of Clinical Medicine Research
keyword
keyword
161966
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"